Article
Rerouting the drug response: Overcoming metabolic adaptation in KRAS-mutant cancers.
Science signaling - 18 Oct 2022
Moss Deborah Y, McCann Christopher, Kerr Emma M
Abstract excerpt
Mutations in guanosine triphosphatase KRAS are common in lung, colorectal, and pancreatic cancers. The constitutive activity of mutant KRAS and its downstream signaling pathways induces metabolic rewiring in tumor cells that can promote resistance to existing therapeutics. In this review, we discuss the metabolic pathways that are altered in response to treatment and those that can, in turn, alter treatment...
Topics
- Humans
- Proto-Oncogene Proteins p21(ras)
- Mutation
- Pancreatic Neoplasms
- Signal Transduction
- Guanosine
- Cell Line, Tumor
- Tumor Microenvironment